This outcome may be due to the absence of sustained positive changes in the immune effector cell population during prolonged TKI therapy, alongside a reduction in CD8+ T cell and macrophage infiltration and an increase in tumor cell PD-L1 expression upon developing TKI resistance [12,13]. The gene discussed is CD8A; the disease is neoplasm.